ReviewJournal of personalized medicine2022
Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma.
Review in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Biologic Therapies and Biomarkers in Severe Childhood Asthma: A Systematic Review of Omalizumab and Mepolizumab.Pediatric pulmonology · 2026Pooled it
- Uptake and Use of Biologic Therapies in Paediatric Immune-Mediated Inflammatory Diseases: An Australian Population-Based Study.Pharmacoepidemiology and drug safety · 2026Article
- Anti-DENV IgE correlates with dengue severity and triggers FcεRI-dependent basophil activation inhibited by Omalizumab.Scientific reports · 2026Article
- Influence of genetic polymorphisms on omalizumab clinical response in pediatric severe asthma: a pilot study.Frontiers in pharmacology · 2026Article
- Health care resource utilization of patients with asthma and food allergy initiating omalizumab.The journal of allergy and clinical immunology. Global · 2025Article
- Traditional Chinese Medicine for Pediatric Allergic Diseases.Current allergy and asthma reports · 2025Review
- Eosinophil-Driven vs. Eosinophil-Associated Severe Asthma: Practical Implications for Target Treatment.International journal of molecular sciences · 2025Review
- Tezepelumab for early-onset severe allergic asthma with persistent airflow limitation and small airway dysfunction: a treatable traits approach.Drugs in context · 2025Article
- The potential role of nanobodies in asthma therapy.Frontiers in pharmacology · 2024Review
- Omalizumab for the reduction of allergic reactions to foods: a narrative review.Frontiers in allergy · 2024Review
- Dimethyl fumarate alleviates allergic asthma by strengthening the Nrf2 signaling pathway in regulatory T cells.Frontiers in immunology · 2024Article
- Factors influencing poor response to type 2 targeted therapies in severe asthma: a retrospective cohort study.BMC pulmonary medicine · 2023Article
- Review
- B Lineage Cells and IgE in Allergic Rhinitis and CRSwNP and the Role of Omalizumab Treatment.American journal of rhinology & allergy · 2023Review
- Effects of biological therapies on patients with Type-2 high asthma and comorbid obesity.Frontiers in pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Omalizumab is the first monoclonal antibody that was globally approved as a personalized treatment option for patients with moderate-to-severe allergic asthma. This review summarizes the knowledge of almost two decades of use of omalizumab to answer some important everyday clinical practice questions, concerning its efficacy and safety and its association with other asthma-related and drug-related parameters. Evidence suggests that omalizumab improves asthma control and reduces the incidence and frequency of exacerbations in patients with severe allergic asthma. Omalizumab is also effective in those patients in reducing corticosteroid use and healthcare utilization, while it also seems to improve lung function. Several biomarkers have been recognized in predicting its efficacy in its target group of patients, while the optimal duration for evaluating its efficacy is between 16 and 32 weeks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.